Key result
Prostaglandin E1 undergoes Cochrane protocol evaluation for maintaining ductal patency in neonates with ductus-dependent lesions.
Why the study?
The effectiveness and safety of prostaglandin E1 for maintaining ductus arteriosus patency and reducing mortality in neonates with ductal-dependent cardiac lesions require evaluation.
Does Prostaglandin E1 maintain patency of the ductus arteriosus and decrease mortality in neonates with ductus-dependent cardiac lesions?
Population
Neonates with ductus-dependent cardiac lesions
Comparison
Prostaglandin E1 versus no PGE1 or other interventions
Design
Cochrane systematic review protocol
Follow-up
Short term (<120 hours) and long term (≥120 hours)
Authors
Loading...
No immediate change to PGE1 use in duct-dependent lesions; protocol leaves open definitive efficacy and safety assessment.
Does Prostaglandin E1 maintain patency of the ductus arteriosus and decrease mortality in neonates with ductus-dependent cardiac lesions?
This protocol outlines a planned Cochrane Review to assess the efficacy and safety of Prostaglandin E1 for maintaining ductal patency in neonates with ductus-dependent cardiac lesions.
Hundalani et al. (2014) studied this question. Prostaglandin E1 is being evaluated in a Cochrane Review protocol to determine its effectiveness and safety for maintaining ductal patency in neonates with ductus-dependent cardiac lesions.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: